Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
|Articles|December 9, 2021
Florida Cancer Specialists & Research Institute Announces Senior Leadership Promotions & Appointments
Promotions and additions to the senior leadership team of Florida Cancer Specialists & Research Institute.
Advertisement
Fort Myers, Florida —
- Chris Chadwick has joined FCS as vice president of Service Delivery & Infrastructure
- Inga Gonzalez has been promoted to senior vice president of Practice Operations
- John Mills has been promoted to vice president of Pharmacy Services
- Marilyn Morales, EdS, MS, MBA, LBBP, CPT, has been promoted to senior vice president of Organizational Effectiveness and Learning
- Amy Pacey, MBA, SPHR, has joined FCS as senior vice president of People & Culture
- Jeffrey Rubin has been promoted to senior vice president of Practice Operations
FCS chief executive officer Nathan H. Walcker said, “These individuals bring a depth of diversity, talent, skill, and expertise that is valued and so vital to our ongoing success. Collectively, they will help to further enhance our national reputation for exceptional and compassionate patient.”
Advertisement
Related to this article
ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.
IL-23 inhibitor risankizumab outperforms TYK2 inhibitor deucravacitinib for PASI 90 in biologic-naive moderate plaque psoriasis.
Dupilumab cut hand eczema severity (59.8% vs 15.2% with placebo), regardless of a patient's atopic history.
Christos Vaklavas, MD, discussed barriers limiting rural oncology access and challenges to adopting resource-intensive therapies.
FDA cut required monitoring for tarlatamab’s first 2 doses from 22-24 hours to 6-8 hours, easing a barrier to community cancer care.
Shiven B. Patel, MD, MBA, shares strategies for closing biomarker testing gaps, including among patients with non–small cell lung cancer.
The ESC's 2026 heart failure guidelines overhaul HF classification, rename therapy categories, and add a new HFpEF recommendation.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
Aspirin's CRC Benefit Narrows to PIK3CA Exon 9/20 Mutations
4
Across the US, Obesity Care Still Lacks an Owner
5